PMID- 32555927
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220204
IS  - 1680-0745 (Electronic)
IS  - 1995-1892 (Print)
IS  - 1015-9657 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Jul/Aug
TI  - Short-term efficacy and safety of levosimendan in patients with chronic systolic 
      heart failure.
PG  - 196-200
LID - 10.5830/CVJA-2020-008 [doi]
AB  - The objective was to investigate and evaluate the short-term efficacy and safety 
      of levosimendan in patients with chronic systolic heart failure. Forty-nine 
      patients with chronic systolic heart failure during acute decompensation were 
      randomly divided into a levosimendan group (26 cases) and a control group (23 
      cases). The control group received only routine treatment, while the levosimendan 
      group received a levosimendan bolus with a load of 12 microg/kg, in addition to the 
      same routine treatment as the control group. After 48 hours of treatment, 
      N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in the levosimendan 
      group were significantly lower than those in the control group. In addition, the 
      left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) 
      cardiac function scores of the levosimendan group were significantly higher and 
      more improved than those of the control group seven days after treatment, but 
      there was no significant difference in the left ventricular end-diastolic 
      diameter between the two groups. Furthermore, 48 hours after treatment, there 
      were no significant differences in potassium, haemoglobin, haematocrit and 
      creatinine levels between the levosimendan and control groups. During the whole 
      hospitalisation, there was one case of sudden death in the control group and one 
      case of palpitations in the levosimendan group, and no hypotension or severe 
      hypokalaemia occurred in either group. Levosimendan significantly improved 
      NT-proBNP and LVEF in patients with chronic systolic heart failure, and improved 
      NYHA cardiac function classification without significant cardiovascular events. 
      Levosimendan is therefore effective and safe in the short-term treatment of 
      chronic systolic heart failure.
FAU - Cui, Xiao-Ran
AU  - Cui XR
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Yang, Xiao-Hong
AU  - Yang XH
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Li, Rui-Bin
AU  - Li RB
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Wang, Dong
AU  - Wang D
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Jia, Min
AU  - Jia M
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Bai, Long
AU  - Bai L
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Zhang, Ji-Dong
AU  - Zhang JD
AD  - The Sixth Department of Cardiovascular Medicine, Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China. Email: zhangjidong78@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200612
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/adverse effects/*therapeutic use
MH  - China
MH  - Chronic Disease
MH  - Female
MH  - Heart Failure, Systolic/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Recovery of Function
MH  - Simendan/adverse effects/*therapeutic use
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left/*drug effects
PMC - PMC8762782
OTO - NOTNLM
OT  - chronic systolic heart failure
OT  - function evaluation
OT  - levosimendan
EDAT- 2020/06/20 06:00
MHDA- 2020/11/11 06:00
PMCR- 2020/07/01
CRDT- 2020/06/20 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/07/01 00:00 [pmc-release]
AID - 10.5830/CVJA-2020-008 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2020 Jul/Aug;31(4):196-200. doi: 10.5830/CVJA-2020-008. Epub 
      2020 Jun 12.